BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

603 related articles for article (PubMed ID: 27593105)

  • 41. Hydrophilic bile acids prevent liver damage caused by lack of biliary phospholipid in
    Wang R; Sheps JA; Liu L; Han J; Chen PSK; Lamontagne J; Wilson PD; Welch I; Borchers CH; Ling V
    J Lipid Res; 2019 Jan; 60(1):85-97. PubMed ID: 30416103
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Hepatic overexpression of murine Abcb11 increases hepatobiliary lipid secretion and reduces hepatic steatosis.
    Figge A; Lammert F; Paigen B; Henkel A; Matern S; Korstanje R; Shneider BL; Chen F; Stoltenberg E; Spatz K; Hoda F; Cohen DE; Green RM
    J Biol Chem; 2004 Jan; 279(4):2790-9. PubMed ID: 14570929
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comprehensive bile acid profiling in hereditary intrahepatic cholestasis: Genetic and clinical correlations.
    Liu T; Wang RX; Han J; Hao CZ; Qiu YL; Yan YY; Li LT; Wang NL; Gong JY; Lu Y; Zhang MH; Xie XB; Yang JC; You YJ; Li JQ; Knisely AS; Borchers CH; Ling V; Wang JS
    Liver Int; 2018 Sep; 38(9):1676-1685. PubMed ID: 29412511
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Vesicle- and Hepatocyte-Based Assays for Identification of Drug Candidates Inhibiting BSEP Function.
    Van Brantegem P; Deferm N; Qi B; De Vocht T; Annaert P
    Methods Mol Biol; 2019; 1981():55-73. PubMed ID: 31016647
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Genetic cholestasis, causes and consequences for hepatobiliary transport.
    Jansen PL; Sturm E
    Liver Int; 2003 Oct; 23(5):315-22. PubMed ID: 14708891
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Bsep/Abcb11 knockout ameliorates Schistosoma mansoni liver pathology by reducing parasite fecundity.
    Macháček T; Fuchs CD; Winkelmann F; Frank M; Scharnagl H; Stojakovic T; Sombetzki M; Trauner M
    Liver Int; 2023 Nov; 43(11):2469-2478. PubMed ID: 37641872
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Wedelolactone alleviates cholestatic liver injury by regulating FXR-bile acid-NF-κB/NRF2 axis to reduce bile acid accumulation and its subsequent inflammation and oxidative stress.
    Wang MQ; Zhang KH; Liu FL; Zhou R; Zeng Y; Chen AL; Yu Y; Xia Q; Zhu CC; Lin CZ
    Phytomedicine; 2024 Jan; 122():155124. PubMed ID: 38014837
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A novel murine model of reversible bile duct obstruction demonstrates rapid improvement of cholestatic liver injury.
    Taylor SA; Yeap XY; Wang JJ; Gromer KD; Kriegermeier A; Green RM; Zhang ZJ
    Physiol Rep; 2020 May; 8(10):e14446. PubMed ID: 32441483
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Protective effect of herbal medicine Huangqi decoction against chronic cholestatic liver injury by inhibiting bile acid-stimulated inflammation in DDC-induced mice.
    Li WK; Wang GF; Wang TM; Li YY; Li YF; Lu XY; Wang YH; Zhang H; Liu P; Wu JS; Ma YM
    Phytomedicine; 2019 Sep; 62():152948. PubMed ID: 31129431
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of bile duct ligation on bile acid composition in mouse serum and liver.
    Zhang Y; Hong JY; Rockwell CE; Copple BL; Jaeschke H; Klaassen CD
    Liver Int; 2012 Jan; 32(1):58-69. PubMed ID: 22098667
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Levels of plasma membrane expression in progressive and benign mutations of the bile salt export pump (Bsep/Abcb11) correlate with severity of cholestatic diseases.
    Lam P; Pearson CL; Soroka CJ; Xu S; Mennone A; Boyer JL
    Am J Physiol Cell Physiol; 2007 Nov; 293(5):C1709-16. PubMed ID: 17855769
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Targeted inactivation of sister of P-glycoprotein gene (spgp) in mice results in nonprogressive but persistent intrahepatic cholestasis.
    Wang R; Salem M; Yousef IM; Tuchweber B; Lam P; Childs SJ; Helgason CD; Ackerley C; Phillips MJ; Ling V
    Proc Natl Acad Sci U S A; 2001 Feb; 98(4):2011-6. PubMed ID: 11172067
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Systemic ASBT inactivation protects against liver damage in obstructive cholestasis in mice.
    Kunst RF; de Waart DR; Wolters F; Duijst S; Vogels EW; Bolt I; Verheij J; Beuers U; Oude Elferink RPJ; van de Graaf SFJ
    JHEP Rep; 2022 Nov; 4(11):100573. PubMed ID: 36160754
    [TBL] [Abstract][Full Text] [Related]  

  • 54. BSEP inhibition: in vitro screens to assess cholestatic potential of drugs.
    Kis E; Ioja E; Rajnai Z; Jani M; Méhn D; Herédi-Szabó K; Krajcsi P
    Toxicol In Vitro; 2012 Dec; 26(8):1294-9. PubMed ID: 22120137
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver.
    Stieger B; Fattinger K; Madon J; Kullak-Ublick GA; Meier PJ
    Gastroenterology; 2000 Feb; 118(2):422-30. PubMed ID: 10648470
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Nifuroxazide mitigates cholestatic liver injury by synergistic inhibition of Il-6/Β-catenin signaling and enhancement of BSEP and MDRP
    Nazmy EA; Helal MG; Said E
    Int Immunopharmacol; 2021 Oct; 99():107931. PubMed ID: 34247051
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cholestatic effect of large bilirubin loads and cholestasis protection conferred by cholic acid co-infusion: a molecular and ultrastructural study.
    Labori KJ; Arnkvaern K; Bjørnbeth BA; Press CM; Raeder MG
    Scand J Gastroenterol; 2002 May; 37(5):585-96. PubMed ID: 12059062
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cholestatic potential of troglitazone as a possible factor contributing to troglitazone-induced hepatotoxicity: in vivo and in vitro interaction at the canalicular bile salt export pump (Bsep) in the rat.
    Funk C; Ponelle C; Scheuermann G; Pantze M
    Mol Pharmacol; 2001 Mar; 59(3):627-35. PubMed ID: 11179459
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The mechanism of increased biliary lipid secretion in mice with genetic inactivation of bile salt export pump.
    Gooijert KE; Havinga R; Wolters H; Wang R; Ling V; Tazuma S; Verkade HJ
    Am J Physiol Gastrointest Liver Physiol; 2015 Mar; 308(5):G450-7. PubMed ID: 25552583
    [TBL] [Abstract][Full Text] [Related]  

  • 60. MYO5B and bile salt export pump contribute to cholestatic liver disorder in microvillous inclusion disease.
    Girard M; Lacaille F; Verkarre V; Mategot R; Feldmann G; Grodet A; Sauvat F; Irtan S; Davit-Spraul A; Jacquemin E; Ruemmele F; Rainteau D; Goulet O; Colomb V; Chardot C; Henrion-Caude A; Debray D
    Hepatology; 2014 Jul; 60(1):301-10. PubMed ID: 24375397
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.